company background image
MRNS

Marinus Pharmaceuticals NasdaqGM:MRNS Stock Report

Last Price

US$4.18

Market Cap

US$199.5m

7D

-12.9%

1Y

-61.0%

Updated

06 Dec, 2022

Data

Company Financials +
MRNS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MRNS Stock Overview

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.

Marinus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Marinus Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.18
52 Week HighUS$13.15
52 Week LowUS$3.97
Beta1.06
1 Month Change-26.15%
3 Month Change-34.17%
1 Year Change-60.97%
3 Year Change-18.99%
5 Year Change-85.82%
Change since IPO-86.94%

Recent News & Updates

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Recent updates

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Nov 04
Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Apr 14
We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 10
Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?

Jan 07
Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?

Shareholder Returns

MRNSUS PharmaceuticalsUS Market
7D-12.9%0.5%-0.4%
1Y-61.0%13.2%-20.6%

Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 15% over the past year.

Return vs Market: MRNS underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is MRNS's price volatile compared to industry and market?
MRNS volatility
MRNS Average Weekly Movement10.1%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: MRNS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MRNS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003113Scott Braunsteinhttps://marinuspharma.com

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.

Marinus Pharmaceuticals, Inc. Fundamentals Summary

How do Marinus Pharmaceuticals's earnings and revenue compare to its market cap?
MRNS fundamental statistics
Market CapUS$199.48m
Earnings (TTM)-US$14.14m
Revenue (TTM)US$19.84m

10.1x

P/S Ratio

-14.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRNS income statement (TTM)
RevenueUS$19.84m
Cost of RevenueUS$74.11m
Gross Profit-US$54.28m
Other Expenses-US$40.13m
Earnings-US$14.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin-273.62%
Net Profit Margin-71.31%
Debt/Equity Ratio86.3%

How did MRNS perform over the long term?

See historical performance and comparison